natgillin/translations-raw huggingface dataset:
In these trials, patients were initially required to be stable on the lowest effective dose of antiParkinsonian medicinal products (dopamine agonist) and to remain on the same anti-Parkinsonian medicinal products and dosages throughout the study.
V teh preskušanjih je bilo potrebno, da se je zdravstveno stanje bolnikov najprej ustalilo ob prejemanju najnižjega učinkovitega odmerka antiparkinsonskih zdravil (dopaminskih agonistov) ter da so ves čas študije prejemali ista antiparkinsonska zdravila v enakih odmerkih.
In two of two placebo and two of three comparator controlled trials with over 2,900 schizophrenic patients presenting with both positive and negative symptoms, olanzapine was associated with statistically significantly greater improvements in negative as well as positive symptoms.
Pri dveh od dveh s placebom kontroliranih in dveh od treh primerjalno kontroliranih preskušanjih pri več kot 2900 bolnikih s shizofrenijo, ki so kazali tako pozitivne kot negativne simptome, je bil olanzapin povezan s statistično značilnim večjim izboljšanjem negativnih in tudi pozitivnih simptomov.
In cases of moderate hepatic insufficiency (cirrhosis, Child-Pugh Class A or B), the starting dose should be 5 mg and only increased with caution.
V primerih zmerno okvarjenega delovanja jeter (ciroza, Child-Pugh razreda A ali B) mora biti začetni odmerek 5 mg in se lahko zvišuje le previdno.
If you suffer from any of the following illnesses tell your doctor as soon as possible:
Če imate katero od spodaj naštetih bolezni, čimprej povejte zdravniku:
Dose escalation, when indicated, should be conservative in such patients (see sections 4.5 and 5.2).
Višanje odmerka, kadar je to indicirano, naj bo pri takih bolnikih previdno (glejte poglavji 4.5 in 5.2).
If this happens after you have been given Olanzapine Mylan tell your doctor.
Če se vam to zgodi po tem, ko ste prejeli zdravilo Olanzapin Mylan, povejte zdravniku.
Dogs tolerated single oral doses up to 100 mg/kg without mortality.
Psi so prenesli enkratne peroralne odmerke do 100 mg/kg brez smrtnega izida.
Hyperglycaemia and diabetes
Hiperglikemija in diabetes
The following table summarises the adverse reactions reported with a greater frequency in adolescent patients (aged 13-17 years) than in adult patients or adverse reactions only identified during short-term clinical trials in adolescent patients.
Naslednja tabela vključuje neželene učinke, ki so jih poročali z višjo pogostnostjo pri mladostnikih (starih 13 - 17 let) kot pri odraslih bolnikih ali neželene učinke, ki so jih ugotovili samo v kratkoročnih kliničnih preskušanjih pri mladostnikih.
Elevated triglyceride levels2,5
Zvišane ravni trigliceridov2,5
In patients with Parkinson's disease Olanzapine Mylan may worsen the symptoms.
Pri bolnikih s Parkinsonovo boleznijo lahko zdravilo Olanzapin Mylan poslabša simptome.
The plasma clearance of olanzapine is lower in elderly versus young subjects, in females versus males, and in non-smokers versus smokers.
Plazemski očistek olanzapina je manjši pri starejših v primerjavi z mlajšimi, pri ženskah v primerjavi z moškimi in pri nekadilcih v primerjavi s kadilci.
The magnitude of weight gain and the proportion of adolescent patients who had clinically significant weight gain were greater with long-term exposure (at least 24 weeks) than with short-term exposure.
Obseg povečanja telesne mase ter razmerje mladostnikov, ki so imeli klinično značilno zvečanje telesne mase, sta bila višja pri dolgoročni izpostavljenosti (najmanj 24 tednov) kot pri kratkoročni izpostavljenosti.
If a new manic, mixed, or depressive episode occurs, olanzapine treatment should be continued (with dose optimisation as needed), with supplementary therapy to treat mood symptoms, as clinically indicated.
Če se pojavi nova manična, mešana ali depresivna epizoda, je treba zdravljenje z olanzapinom nadaljevati (po potrebi s prilagajanjem odmerka) z dopolnilno terapijo za zdravljenje simptomov razpoloženja, kot je klinično indicirano.
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
Reakcija na zdravilo z eozinofilijo in sistemskimi simptomi (DRESS)
There is no specific antidote for olanzapine.
Za olanzapin ni specifičnega antidota.
You should take your Olanzapine Mylan tablets once a day following the advice of your doctor.
Olanzapin Mylan tablete jemljite enkrat na dan, in sicer upoštevajte nasvet zdravnika.
In a retrospective observational cohort study, the risk of presumed sudden cardiac death in patients treated with olanzapine was approximately twice the risk in patients not using antipsychotics.
V retrospektivni opazovalni kohortni študiji so ugotovili, da je bilo tveganje za domnevno nenadno srčno smrt pri bolnikih, ki so se zdravili z olanzapinom, približno dvakrat večje kot pri bolnikih, ki niso jemali antipsihotikov.
In the early stages of treatment, some people may feel dizzy or faint (with a slow heart rate), especially when getting up from a lying or sitting position.
Nekateri ljudje imajo lahko v začetnih obdobjih zdravljenja občutek omotice ali oslabelosti (z upočasnjenim srčnim utripom), zlasti pri vstajanju iz ležečega ali sedečega položaja, ki običajno spontano izzveni.
After oral administration, the mean terminal elimination half-life of olanzapine in healthy subjects varied on the basis of age and gender.
Po peroralnem dajanju se je srednji končni razpolovni čas izločanja olanzapina pri zdravih osebah razlikoval glede na starost in spol.
• carbamazepine (an anti-epileptic and mood stabiliser), fluvoxamine (an antidepressant) or ciprofloxacin (an antibiotic) - it may be necessary to change your Olanzapine Mylan dose.
• karbamazepin (antiepileptik in stabilizator razpoloženja), fluvoksamin (antidepresiv) ali ciprofloksacin (antibiotik) - morda bo potrebno spremeniti vaš odmerek zdravila Olanzapin
Olanzapine also demonstrated comparable efficacy results to haloperidol in terms of the proportion of patients in symptomatic remission from mania and depression at 6 and 12 weeks.
Olanzapin je prav tako pokazal rezultate učinkovitosti, primerljive s haloperidolom, glede na delež bolnikov v simptomatski remisiji manije in depresije po 6 in 12 tednih.
The metabolism of olanzapine may be induced by smoking and carbamazepine, which may lead to reduced olanzapine concentrations.
Presnovo olanzapina lahko pospešita kajenje in karbamazepin, kar lahko povzroči znižane koncentracije olanzapina.
Long-term olanzapine treatment (up to 12 months) for recurrence prevention in patients with bipolar disorder was associated with an increase of  7 % from baseline body weight in 39.9 % of patients.
Dolgoročno zdravljenje z olanzapinom (do 12 mesecev) za preprečevanje ponovnega pojava bolezni pri bolnikih z bipolarno motnjo je bilo povezano s povečanjem telesne mase za ≥ 7 % z osnove pri 39,9 % bolnikov.
Olanzapine also showed a statistically significant advantage over placebo in terms of preventing either recurrence into mania or recurrence into depression.
Olanzapin je pokazal tudi statistično značilno prednost pred placebom glede preprečevanja ponovnega pojava ali manije ali depresije.
Absolute oral bioavailability relative to intravenous administration has not been determined.
Absolutna peroralna biološka uporabnost glede na intravensko dajanje ni bila določena.
It is important that you carry on taking Olanzapine Mylan for as long as your doctor tells you.
Pomembno je, da nadaljujete z jemanjem zdravila Olanzapin Mylan tako dolgo, kot vam naroči zdravnik.
• Tell the doctor if you or someone else in your family has a history of blood clots, as medicines like these have been associated with the formation of blood clots.
- Če ste imeli vi ali kdo v vaši družini v preteklosti pojav krvnih strdkov, morate o tem obvestiti zdravnika, saj lahko zdravila, kot je to, povzročijo nastanek krvnih strdkov.
In cases where hepatitis (including hepatocellular, cholestatic or mixed liver injury) has been diagnosed, olanzapine treatment should be discontinued.
V primerih, kjer je ugotovljen hepatitis (vključno s hepatocelularno, holestatsko ali mešano okvaro jeter), je treba zdravljenje z olanzapinom prekiniti.
Sudden cardiac death
Nenadna srčna smrt
The proportion of patients who had adverse, clinically significant changes in weight gain, glucose, total/LDL/HDL cholesterol or triglycerides increased over time.
Delež bolnikov, ki so imeli neželene, klinično značilne spremembe telesne mase, glukoze, celokupnega/LDL/HDL holesterola ali trigliceridov se je s časom povečal.
The magnitude of changes in fasting total cholesterol, LDL cholesterol, triglycerides, and prolactin (see sections 4.4 and 4.8) were greater in adolescents than in adults.
Obseg sprememb v celokupnem holesterolu na tešče, LDL holesterolu, trigliceridih in prolaktinu (glejte poglavji 4.4 in 4.8) je bil večji pri mladostnikih kot pri odraslih.
Therapeutic monitoring of valproate plasma levels did not indicate that valproate dosage adjustment is required after the introduction of concomitant olanzapine.
Terapevtsko spremljanje plazemskih koncentracij valproata ni pokazalo, da bi bila potrebna prilagoditev odmerka valproata po uvedbi sočasnega zdravljenja z olanzapinom.
Ventricular tachycardia/fibrillation , sudden death (see section 4.4)11
Prekatna tahikardija/fibrilacija , nenadna smrt (glejte poglavje 4.4)11
Very common adverse reactions associated with the use of olanzapine in this patient group were abnormal gait and falls.
Zelo pogosta neželena učinka povezana z uporabo olanzapina v tej skupini bolnikov sta bila neobičajna hoja in padci.
117 Allée des Parcs 69800 Saint-Priest France
117 Allée des Parcs 69800 Saint-Priest Francija
Very common: Decreased total bilirubin, increased GGT, elevated plasma prolactin levels16.
Zelo pogosti: Nizek celokupni bilirubin, visok GGT, zvišane plazemske koncentracije prolaktina16
Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi to zdravilo neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
The efficacy of olanzapine was not established in these trials.
V teh preskušanjih niso ugotavljali učinkovitosti olanzapina.
In the study, the risk of olanzapine was comparable to the risk of atypical antipsychotics included in a pooled analysis.
Študija je pokazala, da je bilo tveganje pri olanzapinu primerljivo s tveganjem pri atipičnih antipsihotikih, vključenih v skupno analizo.
Very rare side effects include serious allergic reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
Zelo redki neželeni učinki vključujejo resne alergijske reakcije, kot je reakcija na zdravilo z eozinofilijo in sistemskimi simptomi (DRESS - 'Drug Reaction with Eosinophilia and Systemic Symptoms').
If this has happened to you, tell your doctor.
Če se to pojavi pri vas, obvestite zdravnika.
If this happens, contact your doctor at once.
Če se zgodi kaj takega, se nemudoma obrnite na zdravnika.
However the risk of tardive dyskinesia increases with long term exposure, and therefore if signs or symptoms of tardive dyskinesia appear in a patient on olanzapine, a dose reduction or discontinuation should be considered.
Vendar pa tveganje za tardivne diskinezije narašča s trajanjem zdravljenja in je zato ob pojavu znakov ali simptomov tardivnih diskinezij pri bolniku, ki prejema olanzapin, treba razmisliti o znižanju odmerka ali ukinitvi zdravila.
Olanzapine is not indicated for use in the treatment of children and adolescents.
Olanzapin ni indiciran za uporabo pri zdravljenju otrok in mladostnikov.
The clinical consequences are likely to be limited, but clinical monitoring is recommended and an increase of olanzapine dose may be considered if necessary (see section 4.2).
Klinične posledice so verjetno omejene, vendar je priporočeno spremljanje kliničnega stanja in zvišanje odmerka olanzapina, če je potrebno (glejte poglavje 4.2).
What Olanzapine Mylan is and what it is used for What you need to know before you take Olanzapine Mylan How to take Olanzapine Mylan Possible side effects
Kaj je zdravilo Olanzapin Mylan in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Olanzapin Mylan Kako jemati zdravilo Olanzapin Mylan Možni neželeni učinki
Effects on haematology parameters were found in each species, including dose-related reductions in circulating leukocytes in mice and non-specific reductions of circulating leukocytes in rats; however, no evidence of bone marrow cytotoxicity was found.
Pri vsaki vrsti so odkrili učinke na hematološke parametre, vključno z z odmerkom povezanimi znižanji koncentracij levkocitov v obtoku pri miših in nespecifičnim znižanjem koncentracije levkocitov v obtoku pri podganah; vendar pa niso našli dokazov citotoksičnosti za kostni mozeg.
Potential for olanzapine to affect other medicinal products Olanzapine may antagonise the effects of direct and indirect dopamine agonists.
Zmožnost vplivanja olanzapina na druga zdravila Olanzapin lahko nasprotuje učinkom direktnih in indirektnih dopaminskih agonistov.
A decrease in the dose of olanzapine should be considered if treatment with an inhibitor of CYP1A2 is initiated.
Upoštevati je treba znižanje odmerka olanzapina, če se uvede zdravljenje z zaviralcem CYP1A2.
Hepatitis (including hepatocellular, cholestatic or mixed liver injury)11
Hepatitis (vključno s hepatocelularno, holestatsko ali mešano okvaro jeter)11
While olanzapine demonstrated anticholinergic activity in vitro, experience during the clinical trials revealed a low incidence of related events.
Medtem ko je olanzapin pokazal antiholinergično delovanje v pogojih in vitro, so izkušnje kliničnih preskušanj razkrile majhno incidenco s tem povezanih dogodkov.
The concomitant use of olanzapine with anti-Parkinsonian medicinal products in patients with Parkinson's disease and dementia is not recommended (see section 4.4).
Sočasna uporaba olanzapina z antiparkinsonskimi zdravili pri bolnikih s Parkinsonovo boleznijo in demenco ni priporočena (glejte poglavje 4.4).
Olanzapine should be used cautiously in patients who have a history of seizures or are subject to factors which may lower the seizure threshold.
Olanzapin je treba uporabljati previdno pri bolnikih, ki so imeli v preteklosti epileptične napade ali so podvrženi dejavnikom, ki bi lahko znižali prag za epileptične napade.
Olanzapine does not inhibit the main CYP450 isoenzymes in vitro (e.g. 1A2, 2D6, 2C9, 2C19, 3A4).
Olanzapin ne zavira glavnih izoencimov CYP450 v pogojih in vitro (npr. 1A2, 2D6, 2C9, 2C19, 3A4).
• of these symptoms seek medical advice immediately;
Če opazite katerega od teh simptomov, nemudoma poiščite zdravniško pomoč;
Animal behavioural studies with olanzapine indicated 5HT, dopamine, and cholinergic antagonism, consistent with the receptor-binding profile.
Vedenjske študije z olanzapinom na živalih so kazale na 5HT, dopaminski in holinergični antagonizem v skladu s profilom vezave na receptorje.
In the same clinical trials, cerebrovascular adverse events (CVAE e.g., stroke, transient ischaemic attack), including fatalities, were reported.
V istih kliničnih preskušanjih so poročali o cerebrovaskularnih neželenih dogodkih (cerebrovascular adverse events - CVAE, npr. o možganski kapi, tranzitorni ishemični ataki), vključno s smrtnimi izidi.
Standard procedures for management of overdose may be indicated (i.e. gastric lavage, administration of activated charcoal).
Lahko so indicirani standardni postopki za zdravljenje prevelikega odmerjanja (t. j. izpiranje želodca, dajanje aktivnega oglja).
Cytochromes P450CYP1A2 and P450-CYP2D6 contribute to the formation of the N-desmethyl and 2-hydroxymethyl metabolites, both exhibited significantly less in vivo pharmacological activity than olanzapine in animal studies.
Citokroma P450-CYP1A2 in P450CYP2D6 prispevata k tvorbi N-demetilnih in 2-hidroksimetilnih metabolitov, oboji so v študijah na živalih pokazali pomembno manj farmakološke aktivnosti in vivo kot olanzapin.
An allergic reaction may be recognised as a rash, itching, a swollen face, swollen lips or shortness of breath.
Alergijsko reakcijo lahko prepoznamo kot izpuščaj, srbenje, otekel obraz, ustnice ali oteženo dihanje.
Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.
Dodatni znaki lahko vključujejo zvišano kreatin fosfokinazo, mioglobinurijo (rabdomioliza) in akutno ledvično odpoved.
In cytopenic dogs, there were no adverse effects on progenitor and proliferating cells in the bone marrow.
Pri psih z izraženo citopenijo ni bilo neželenih učinkov na progenitorne in proliferirajoče celice v kostnem mozgu.
Olanzapine reduced a conditioned avoidance response, a test indicative of antipsychotic activity, at doses below those producing catalepsy, an effect indicative of motor side-effects.
Olanzapin je zmanjšal pogojeni umaknitveni odziv, test, ki kaže na antipsihotično delovanje, pri odmerkih, nižjih od tistih, ki povzročijo katalepsijo, učinek, ki kaže na motorične neželene učinke.
With long-term exposure (at least 24 weeks), 89.4 % gained ≥ 7 %, 55.3 % gained ≥ 15 % and 29.1 % gained ≥ 25%, of their baseline body weight.
Pri dolgoročni izpostavljenosti (najmanj 24 tednov) jih je 89,4 % pridobilo ≥ 7 %, 55,3 % ≥ 15 % in 29,1 % ≥ 25% od njihove osnovne telesne mase.
12 Adverse event identified from spontaneous post-marketing reporting with frequency estimated at the upper limit of the 95 % confidence interval utilising the Olanzapine Integrated Database.
12 Neželeni učinki, ugotovljeni pri spontanem poročanju v obdobju trženja s pogostostjo, ocenjeno na zgornjo mejo 95-% intervala zaupanja, določeno z uporabo integrirane baze podatkov za olanzapin.
Consult your doctor if your symptoms return but do not stop taking Olanzapine Mylan unless your doctor tells you to.
Če se simptomi povrnejo, se posvetujte z zdravnikom, vendar ne prenehajte jemati zdravila Olanzapin Mylan, če vam tega ne naroči zdravnik.
• A blocked intestine (Paralytic ileus)
• zaporo črevesa (paralitični ileus)
Thus no particular interaction is expected as verified through in vivo studies where no inhibition of metabolism of the following active substances was found: tricyclic antidepressant (representing mostly CYP2D6 pathway), warfarin (CYP2C9), theophylline (CYP1A2) or diazepam (CYP3A4 and 2C19).
Zato ni pričakovati kakega posebnega medsebojnega delovanja, kar je bilo potrjeno s študijami in vivo, kjer niso opazili nobenega zaviranja presnove naslednjih učinkovin: tricikličnih antidepresivov (ki predstavljajo predvsem pot CYP2D6), varfarina (CYP2C9), teofilina (CYP1A2) ali diazepama (CYP3A4 in 2C19).
High Gamma Glutamyltransferase10
Visoke vrednosti gama glutamiltransferaze
Lipid alterations
Spremembe lipidov
However, as clinical experience with olanzapine in patients with concomitant illness is limited, caution is advised when prescribing for patients with prostatic hypertrophy, or paralytic ileus and related conditions.
Ker so klinične izkušnje z olanzapinom pri bolnikih s sočasnimi drugimi boleznimi omejene, se priporoča previdnost pri predpisovanju bolnikom s hipertrofijo prostate ali paralitičnim ileusom in povezanimi stanji.
In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki < 100 nM) for serotonin 5 HT2A/2C, 5 HT3, 5 HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors M1-M5; α1 adrenergic; and histamine H1 receptors.
V predkliničnih študijah je olanzapin pokazal razpon afinitet do receptorjev (Ki; < 100 nM) za serotonin 5-HT2A/2C, 5-HT3, 5-HT6; dopamin D1, D2, D3, D4, D5; holinergičnih muskarinskih receptorjev M1-M5; adrenergičnih 1; in histaminskih H1 receptorjev.
Symptomatic treatment and monitoring of vital organ function should be instituted according to clinical presentation, including treatment of hypotension and circulatory collapse and support of respiratory function.
Glede na klinično sliko je treba uvesti simptomatsko zdravljenje in spremljanje delovanja vitalnih organov, vključno z zdravljenjem hipotenzije in cirkulatorne odpovedi ter podporo dihanja.
Cardiovascular monitoring is necessary to detect possible arrhythmias.
Za odkritje možnih aritmij je nujno spremljati delovanje kardiovaskularnega sistema.
Patients treated with any antipsychotic medicines, including olanzapine, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control.
Bolnike, zdravljene s katerimkoli antipsihotikom, vključno z zdravilom olanzapinom, moramo opazovati za znake in simptome hiperglikemije (kot so polidipsija, poliurija, polifagija in šibkost) ter redno spremljati bolnike s sladkorno boleznijo ali dejavniki tveganja za sladkorno bolezen glede poslabšanja nadzora glukoze.
There were more smokers among subjects with cirrhosis (4/6; 67 %) than among subjects with no hepatic dysfunction (0/3; 0 %).
Med osebami s cirozo (4/6, 67%) je bilo več kadilcev kot med osebami brez jetrne okvare (0/3, 0%).
In comparator studies of one year or less duration, olanzapine was associated with a statistically significant lower incidence of treatment emergent dyskinesia.
V primerjalnih študijah, ki so trajale eno leto ali manj, so olanzapin povezovali s statistično značilno manjšo incidenco diskinezij, ki se pojavijo ob zdravljenju.
For patients who have been receiving olanzapine for treatment of manic episode, continue therapy for preventing recurrence at the same dose.
Pri bolnikih, ki so prejemali olanzapin za zdravljenje manične epizode, nadaljujte zdravljenje za preprečevanje ponovnega pojava bolezni z enakim odmerkom.
Caution should be used if olanzapine is being administered concomitantly with medicinal products known to increase QTc interval (see section 4.4).
Potrebna je previdnost če dajemo olanzapin sočasno z zdravili za katera je znano, da podaljšujejo QTc interval (glejte poglavje 4.4).
Olanzapine is well absorbed after oral administration, reaching peak plasma concentrations within 5 to 8 hours.
Olanzapin se po peroralnem dajanju dobro absorbira, maksimalno plazemsko koncentracijo dosega v 5 do 8 urah.
Only slight to moderate increase in olanzapine clearance has been observed.
Opažali so le blago do zmerno povečanje očistka olanzapina.
Very common: Elevations of hepatic aminotransferases (ALT/AST; see section 4.4).
Zelo pogosti: Zvišane ravni jetrnih aminotransferaz (ALT/AST; glejte poglavje 4.4) Preiskave
The use of olanzapine in the treatment of dopamine agonist associated psychosis in patients with Parkinson's disease is not recommended.
Uporaba olanzapina pri zdravljenju psihoze, povezane z dopaminskimi agonisti, pri bolnikih s Parkinsonovo boleznijo ni priporočena.
In clinical trials, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly and more frequently than with placebo (see section 4.8), and olanzapine was not more effective than placebo in the treatment of psychotic symptoms.
V kliničnih preskušanjih so o poslabšanju parkinsonske simptomatike in halucinacijah poročali zelo pogosto in pogosteje kot pri placebu (glejte poglavje 4.8), olanzapin pa ni bil bolj učinkovit kot placebo pri zdravljenju psihotičnih simptomov.
In addition, a Single Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D2 occupancy than some other antipsychoticand risperidone-responsive patients, while being comparable to clozapine-responsive patients.
Dodatno je SPECT (Single Photon Emission Computed Tomography) slikovna študija pri bolnikih s shizofrenijo razkrila, da so imeli bolniki, ki so se odzivali na olanzapin, nižjo zasedenost striatnih D2 receptorjev kot bolniki, ki so se odzivali na nekatere druge antipsihotike in risperidon, medtem ko je bila primerljiva z bolniki, ki so se odzivali na klozapin.
The predominant pharmacologic activity is from the parent olanzapine.
Prevladujoča farmakološka aktivnost izvira iz samega olanzapina.
• The use of Olanzapine Mylan in elderly patients with dementia is not recommended as it may have serious side effects.
- Uporaba zdravila Olanzapin Mylan ni priporočljiva pri starejših bolnikih z demenco, saj lahko povzroči resne neželene učinke.